Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

Quantum Genomics SA

ALQGC:PAR

Quantum Genomics SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)0.1336
  • Today's Change0.004 / 2.93%
  • Shares traded17.68k
  • 1 Year change-16.92%
  • Beta0.6532
Data delayed at least 15 minutes, as of May 21 2024 14:47 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in EURView more

In 2022, Quantum Genomics SA increased its cash reserves by 15.40%, or 2.09m. Cash Flow from Financing totalled 17.21m or 2,845.38% of revenues. In addition the company used 14.97m for operations while cash used for investing totalled 152.54k.
Cash flow per share-0.0907
Price/Cash flow per share--
Book value per share0.0125
Tangible book value per share0.0125
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.